- We will send in 10–14 business days.
/images/books/11288157/9781588296498.jpg)
- Publisher: Humana Press
- Year: 2006
- Pages: 527
- ISBN-10: 1588296490
- ISBN-13: 9781588296498
- Format: 16.1 x 23.4 x 3.4 cm, hardcover
- Language: English
- SAVE -10% with code: EXTRA
Reverse Transcriptase Inhibitors in Hiv/AIDS Therapy (e-book) (used book) | bookbook.eu
Reviews
Description
A magisterial survey of all aspects of the reverse transcriptase inhibitors (RTIs) used to treat HIV/AIDS, including drug discovery, pharmacology, development of drug resistance, toxicity, and prevention of mother-to-child transmission of HIV/AIDS. The authors synthesize our current understanding of the role of reverse transcriptase in the viral life cycle, describe the discovery and development of eight nucleoside and nucleotide analogs that represent milestones in treatment history, and thoroughly discuss the question of toxicity and resistance to this class of drugs. They also address three non-nucleoside RTIs and their pharmacokinetics and comparative clinical efficacy, new RTIs currently under development, and the impact of approved agents on treatment, in general, and on vertical transmission in the developing world.
EXTRA 10 % discount with code: EXTRA
The promotion ends in 20d.19:27:44
The discount code is valid when purchasing from 10 €. Discounts do not stack.
- Publisher: Humana Press
- Year: 2006
- Pages: 527
- ISBN-10: 1588296490
- ISBN-13: 9781588296498
- Format: 16.1 x 23.4 x 3.4 cm, hardcover
- Language: English English
A magisterial survey of all aspects of the reverse transcriptase inhibitors (RTIs) used to treat HIV/AIDS, including drug discovery, pharmacology, development of drug resistance, toxicity, and prevention of mother-to-child transmission of HIV/AIDS. The authors synthesize our current understanding of the role of reverse transcriptase in the viral life cycle, describe the discovery and development of eight nucleoside and nucleotide analogs that represent milestones in treatment history, and thoroughly discuss the question of toxicity and resistance to this class of drugs. They also address three non-nucleoside RTIs and their pharmacokinetics and comparative clinical efficacy, new RTIs currently under development, and the impact of approved agents on treatment, in general, and on vertical transmission in the developing world.
Reviews